Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA6 | P23280 | 1/20 | 0.31 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.30 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.30 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.30 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.30 |
| ▸ | AHR | P35869 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2152106 | 0.85 | TDP1 (0.34) | TDP1APEX1 | |
| SCHEMBL328794 | 0.83 | TDP1 (0.40) | TDP1APEX1AKR1B1CA1CA2 | |
| SCHEMBL11522162 | 0.79 | TDP1 (0.37) | TDP1APEX1 | |
| SCHEMBL9373547 | 0.79 | TDP1 (0.37) | TDP1APEX1 | |
| SCHEMBL2882117 | 0.79 | TDP1 (0.37) | TDP1APEX1CA2CA4 | |
| SCHEMBL4453850 | 0.79 | TDP1 (0.37) | TDP1APEX1 | |
| SCHEMBL5186322 | 0.79 | TDP1 (0.37) | TDP1APEX1 | |
| SCHEMBL4601560 | 0.79 | TDP1 (0.37) | TDP1APEX1AKR1B1CA1CA2 | |
| SCHEMBL4599386 | 0.77 | TDP1 (0.41) | TDP1APEX1AKR1B1 | |
| SCHEMBL11660852 | 0.76 | TDP1 (0.32) | TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7605207-B2 | Heat resistance; using with polystyrene fthermoplastic foams | BROMINE COMPOUNDS LTD. (IL) | 2009-10-20 | — | — | US | disclosed |
| US-20080281024-A1 | Flame Retardant Bromobenzyl Systems | BROMINE COMPOUNDS LTD. (IL) | 2008-11-13 | — | — | US | disclosed |
| EP-1951798-A2 | FLAME RETARDANT BROMOBENZYL SYSTEMS | Bromine Compounds Ltd. (IL) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007057900-A2 | FLAME RETARDANT BROMOBENZYL SYSTEMS | BROMINE COMPOUNDS LTD. (IL) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080281024-A1 | Flame Retardant Bromobenzyl Systems | PBRM1, PFAS, BPTF | TDP1 542/4885APEX1 3777/4885AKR1B1 1118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.